dapaconazole
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Jan 29, 2014 (NCT03359070)
Timeline
Indications
Studied for
Mechanism of action
- ErgosterolDISRUPTING AGENT
Ergosterol disrupting agent
Chemistry & pharmacology
Loading structure…
SMILES
FC(F)(F)c1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1- Mol. weight
- 415.24 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297506 ↗
Also known as
- 1-(2-(2,4-dichlorophenyl)-2-(4-(trifluoromethyl)benzyloxy)ethyl)-1h-imidazole
- dapaconazole
- dapaconazole
- dapaconazole
- dapaconazole
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03320486 | Phase 3 | Nov 1, 2017 | Biolab Sanus Farmaceutica, Galeno Desenvolvimento de Pesquisas |
| NCT02606383 | Phase 3 | Jun 1, 2016 | Biolab Sanus Farmaceutica, Galeno Desenvolvimento de Pesquisas |
| NCT02824926 | Phase 2 | Jul 1, 2014 | Biolab Sanus Farmaceutica, Galeno Desenvolvimento de Pesquisas, Galeno Desenvolvimento de Pesquisas Clínicas |
| NCT03359070 | Phase 2 | Jan 29, 2014 | Biolab Sanus Farmaceutica, Galeno Desenvolvimento de Pesquisas |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biolab Sanus Farmaceutica | For profit | 4 | 2 | 2 | 2014 |
| Galeno Desenvolvimento de Pesquisas | Academic/Hospital | 4 | 1 | 2 | 2014 |
| Galeno Desenvolvimento de Pesquisas Clínicas | Academic/Hospital | 1 | 1 | 1 | 2014 |
3 organizations
Page 1 / 1